{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:59:06Z","timestamp":1791327546775,"version":"4.3.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.semradonc.2013.01.007","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T19:06:31Z","timestamp":1370459191000},"page":"198-205","source":"Crossref","is-referenced-by-count":18,"title":["Management of Prostate Cancer in Elderly Men"],"prefix":"10.1016","volume":"23","author":[{"given":"Shelly X.","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2013.01.007_bib1","unstructured":"Projections of the population by age and sex for the United States: 2010 to 2050 (NP2008-T12). Washington, DC, U.S. Census Bureau, Statistical Abstract of the United States: 2012, Population Division, 2011"},{"key":"10.1016\/j.semradonc.2013.01.007_bib3","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.285.21.2750","article-title":"Cancer screening in elderly patients: A framework for individualized decision making","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/SPC.0b013e32832e9c80","article-title":"Predicting life expectancy in prostate cancer patients","volume":"3","author":"Jeldres","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.semradonc.2013.01.007_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.semradonc.2013.01.007_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-5347(05)00018-2","article-title":"Predicting life expectancy in men with clinically localized prostate cancer","volume":"175","author":"Cowen","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/01.ju.0000117975.40782.95","article-title":"Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities","volume":"171","author":"Tewari","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5347(01)65964-0","article-title":"The impact of co-morbidity on life expectancy among men with localized prostate cancer","volume":"156","author":"Albertsen","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib9","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2006.10.3820","article-title":"A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer","volume":"25","author":"Walz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib10","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.23502","article-title":"Active surveillance for the management of prostate cancer in a contemporary cohort","volume":"112","author":"Dall'Era","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2013.01.007_bib11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","article-title":"Active surveillance program for prostate cancer: An update of the Johns Hopkins experience","volume":"29","author":"Tosoian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jama.2009.1348","article-title":"Outcomes of localized prostate cancer following conservative management","volume":"302","author":"Lu-Yao","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib14","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa043739","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"352","author":"Bill-Axelson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2013.01.007_bib15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2004.10.062","article-title":"The changing face of low-risk prostate cancer: trends in clinical presentation and primary management","volume":"22","author":"Cooperberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.amjmed.2010.10.016","article-title":"Patterns and correlates of prostate cancer treatment in older men","volume":"124","author":"Roberts","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.semradonc.2013.01.007_bib17","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cncr.25751","article-title":"Overtreatment of men with low-risk prostate cancer and significant comorbidity","volume":"117","author":"Daskivich","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2013.01.007_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.1995.03530080042039","article-title":"Long-term survival among men with conservatively treated localized prostate cancer","volume":"274","author":"Albertsen","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0090-4295(03)00690-3","article-title":"Continued undertreatment of older men with localized prostate cancer","volume":"62","author":"Schwartz","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.semradonc.2013.01.007_bib21","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.2003.09.034","article-title":"Do older men benefit from curative therapy of localized prostate cancer?","volume":"21","author":"Alibhai","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib22","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1001\/jama.296.22.2683","article-title":"2006: Survival associated with treatment vs observation of localized prostate cancer in elderly men","volume":"296","author":"Wong","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2009.01.045","article-title":"Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations","volume":"76","author":"Nguyen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib24","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cncr.24974","article-title":"Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer","volume":"116","author":"Hoffman","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2013.01.007_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1464-410X.2007.07373.x","article-title":"The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases","volume":"101","author":"Walz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.semradonc.2013.01.007_bib26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/dji313","article-title":"30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity","volume":"97","author":"Alibhai","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2013.01.007_bib27","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/01.ju.0000145222.94455.73","article-title":"Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies","volume":"172","author":"Kundu","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jama.283.3.354","article-title":"Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study","volume":"283","author":"Stanford","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2006.06.022","article-title":"Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases","volume":"51","author":"Mohamad","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.urology.2004.12.041","article-title":"Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer","volume":"65","author":"Jani","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.semradonc.2013.01.007_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2005.06.001","article-title":"3D conformal radiation therapy for prostate cancer in elderly patients","volume":"76","author":"Geinitz","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0360-3016(99)00560-X","article-title":"Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response","volume":"47","author":"Skwarchuk","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.eururo.2008.03.026","article-title":"Erectile dysfunction after external beam radiotherapy for prostate cancer","volume":"55","author":"Pinkawa","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib36","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.2011.1333","article-title":"Prediction of erectile function following treatment for prostate cancer","volume":"306","author":"Alemozaffar","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib37","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and treatment factors associated with complications after prostate brachytherapy","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/01.ju.0000107964.61300.f6","article-title":"Predicting quality of life after radical prostatectomy: results from CaPSURE","volume":"171","author":"Hu","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/pcan.2010.33","article-title":"From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer","volume":"13","author":"Daskivich","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2013.01.007_bib40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2013.01.007_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib43","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib44","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014Long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib46","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2013.01.007_bib47","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijrobp.2009.06.038","article-title":"Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group","volume":"77","author":"Nguyen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2008.10.082","article-title":"Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death","volume":"75","author":"D'Amico","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib49","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/annonc\/mds001","article-title":"Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer","volume":"23","author":"Bian","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib50","unstructured":"Bian SX, Kuban DA, Levy LB, et al: The Addition of Short-term Androgen Deprivation Therapy to Dose-Escalated Radiation Therapy Improves Failure-Free Survival For Older Men With Intermediate-Risk Prostate Cancer American Society for Radiation Oncology Annual Meeting, Abstract 1046, Boston, MA, October 29-31, 2012; 2012"},{"key":"10.1016\/j.semradonc.2013.01.007_bib52","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.juro.2008.01.044","article-title":"Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE","volume":"179","author":"Konety","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib53","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib54","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib55","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2013.01.007_bib56","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"2011: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.semradonc.2013.01.007_bib57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.semradonc.2013.01.007_bib58","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2013.01.007_bib59","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.23084","article-title":"Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review","volume":"110","author":"Bylow","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2013.01.007_bib60","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1464-410X.2006.06066.x","article-title":"Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists","volume":"97","author":"Wilke","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.semradonc.2013.01.007_bib61","author":"Howlader"},{"key":"10.1016\/j.semradonc.2013.01.007_bib62","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jnci\/djp262","article-title":"Contemporary risk profile of prostate cancer in the United States","volume":"101","author":"Shao","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429613000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429613000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T19:19:19Z","timestamp":1563131959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429613000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1053429613000180"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2013.01.007","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}